Survivor Stories

Andrew Vartanian

Immediately after being told by his primary care physician that the Abramson Cancer Center is one of the best cancer institutions in the country, Andrew Vartanian made his first appointment. After standard treatments did not work, Andrew's medical team at Penn decided to try a relatively new drug, Erbitux®, a genetically engineered antibody that targets a natural protein on the surface of cancer cells and interferes with their growth. After this therapy, Andrew's cancer stabilized. Andrew's wife accompanies him to his weekly check-ups where he remains very positive because "the top professionals in cancer care are totally focused on my care."


Education and Support Survivor Stories